BioSante Pharma (BPAX) Closes 2.36M Direct Offering; Nets $3.3M

Article Stock Quotes (1) Comments (0)

BioSante Pharmaceuticals, Inc. (Nasdaq: BPAX) today announced the closing of the sale of 2,359,932 shares of its common stock and warrants to purchase up to 1,179,966 additional shares of its common stock in a registered direct offering, resulting in gross cash proceeds to BioSante of $3,475,000. BioSante received net proceeds of approximately $3.3 million after deducting placement agent fees and other offering expenses. Each unit, consisting of one share of common stock and a warrant to purchase 0.5 of a share of common stock, was sold to one institutional investor for a purchase price of $1.4725, which was a premium to the closing price on the day before pricing. The warrants are exercisable immediately at an exercise price of $1.50 per share and will expire on August 17, 2017.

Proceeds from the transaction will be used for general corporate purposes, including increasing the Company’s cash reserve for payment of its 3.125% convertible senior notes due May 1, 2013 and to fund its LibiGel® clinical activities.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Bloomin' Brands (BLMN) Prices 19M Common Stock Secondary Offering
• Acacia Research (ACTG) Enters Settlement with Red Hat (RHT)
• Sprint (S), SoftBank Receive Final State Regulatory Approval in Proposed Deal

Create E-mail Alert Related Categories

Corporate News, Equity Offerings

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?